Streetbeat News

Analyst Ratings

BMY

HALO

MRTX

Bristol Myers Squibb Co (BMY) has released positive topline data from a Phase 3 trial of a subcutaneous formulation of Opdivo for advanced kidney cancer. The formulation uses Halozyme Therapeutics Inc.'s (HALO) recombinant human hyaluronidase. The study met its primary and secondary endpoints. Earlier this month, BMY agreed to acquire Mirati Therapeutics Inc (MRTX) for $4.8 billion.

Portfolio Pulse from Vandana Singh

October 19, 2023 | 2:25 pm

DUOL

B of A Securities analyst Curtis Nagle has reinstated Duolingo (NASDAQ:DUOL) with a Neutral rating and announced a price target of $188.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:24 pm

EGHT

Morgan Stanley analyst Meta Marshall has maintained an Equal-Weight rating on 8x8 (NASDAQ:EGHT) and lowered the price target from $4 to $3.3.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:23 pm

UDMY

B of A Securities analyst Curtis Nagle has reinstated Udemy (NASDAQ:UDMY) with a Buy rating and announced a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:18 pm

LRCX

B. Riley Securities analyst Craig Ellis has maintained a Neutral rating on Lam Research (NASDAQ:LRCX) and raised the price target from $690 to $700.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:17 pm

GS

Unusual options activity has been observed for Goldman Sachs Gr (NYSE:GS), with a split sentiment of 50% bullish and 50% bearish among big-money traders. The options trades include 4 puts amounting to $228,955 and 8 calls amounting to $307,617. The targeted price range for GS over the last 3 months is from $240.0 to $390.0. Analysts from Oppenheimer, JMP Securities, Citigroup, and Morgan Stanley have maintained their ratings on GS with varying price targets.

Portfolio Pulse from Benzinga Insights

October 19, 2023 | 2:16 pm

ABBV

A significant bullish stance on AbbVie (NYSE:ABBV) has been observed through unusual options activity. The sentiment among these big-money traders is split between 60% bullish and 40% bearish. The whales have been targeting a price range from $100.0 to $165.0 for AbbVie over the last 3 months. Morgan Stanley maintains an Overweight rating on AbbVie with a price target of $193, while Raymond James downgraded its action to Outperform with a price target of $177.

Portfolio Pulse from Benzinga Insights

October 19, 2023 | 2:16 pm

BMBL

B of A Securities analyst Curtis Nagle has reinstated Bumble (NASDAQ:BMBL) with a Neutral rating and announced a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:14 pm

CHWY

B of A Securities analyst Curtis Nagle has reinstated Chewy (NYSE:CHWY) with an Underperform rating and announced a $16 price target.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:13 pm

EFC

B. Riley Securities analyst Matt Howlett has initiated coverage on Ellington Financial (NYSE:EFC) with a Buy rating and a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:11 pm